Literature DB >> 25951529

Repurposing a leukocyte elastase inhibitor for neuropathic pain.

Andy D Weyer1, Cheryl L Stucky1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25951529     DOI: 10.1038/nm.3861

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  8 in total

Review 1.  Neuropathic pain needs systematic classification.

Authors:  N B Finnerup; J Scholz; N Attal; R Baron; M Haanpää; P Hansson; S N Raja; A S C Rice; W Rief; M C Rowbotham; D M Simpson; R-D Treede
Journal:  Eur J Pain       Date:  2013-01-21       Impact factor: 3.931

Review 2.  Neuropathic pain: mechanisms and their clinical implications.

Authors:  Steven P Cohen; Jianren Mao
Journal:  BMJ       Date:  2014-02-05

Review 3.  Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment.

Authors:  Ralf Baron; Andreas Binder; Gunnar Wasner
Journal:  Lancet Neurol       Date:  2010-08       Impact factor: 44.182

4.  Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study.

Authors:  Bernhardt G Zeiher; Antonio Artigas; Jean-Louis Vincent; Alexei Dmitrienko; Kimberley Jackson; B Taylor Thompson; Gordon Bernard
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

Review 5.  Deconstructing the neuropathic pain phenotype to reveal neural mechanisms.

Authors:  Christian A von Hehn; Ralf Baron; Clifford J Woolf
Journal:  Neuron       Date:  2012-02-23       Impact factor: 17.173

Review 6.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Authors:  Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace
Journal:  Lancet Neurol       Date:  2015-01-07       Impact factor: 44.182

Review 7.  Clinical utility of the neutrophil elastase inhibitor sivelestat for the treatment of acute respiratory distress syndrome.

Authors:  Naoki Aikawa; Yasushi Kawasaki
Journal:  Ther Clin Risk Manag       Date:  2014-08-05       Impact factor: 2.423

8.  The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase.

Authors:  Lucas Vicuña; David E Strochlic; Alban Latremoliere; Kiran Kumar Bali; Manuela Simonetti; Dewi Husainie; Sandra Prokosch; Priscilla Riva; Robert S Griffin; Christian Njoo; Stefanie Gehrig; Marcus A Mall; Bernd Arnold; Marshall Devor; Clifford J Woolf; Stephen D Liberles; Michael Costigan; Rohini Kuner
Journal:  Nat Med       Date:  2015-04-27       Impact factor: 53.440

  8 in total
  5 in total

Review 1.  Targeting pain at its source in sickle cell disease.

Authors:  Kanika Gupta; Om Jahagirdar; Kalpna Gupta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-03-28       Impact factor: 3.619

2.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

3.  Effects of the neutrophil elastase inhibitor EL-17 in rat adjuvant-induced arthritis.

Authors:  Lorenzo Di Cesare Mannelli; Laura Micheli; Lorenzo Cinci; Mario Maresca; Claudia Vergelli; Alessandra Pacini; Mark T Quinn; Maria Paola Giovannoni; Carla Ghelardini
Journal:  Rheumatology (Oxford)       Date:  2016-03-30       Impact factor: 7.580

4.  Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis.

Authors:  Monokesh K Sen; Mohammed S M Almuslehi; Erika Gyengesi; Simon J Myers; Peter J Shortland; David A Mahns; Jens R Coorssen
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

5.  Sulfonated Nonsaccharide Heparin Mimetics Are Potent and Noncompetitive Inhibitors of Human Neutrophil Elastase.

Authors:  Rami A Al-Horani; Kholoud F Aliter; Srabani Kar; Madhusoodanan Mottamal
Journal:  ACS Omega       Date:  2021-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.